206 related articles for article (PubMed ID: 29618103)
1. The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients With Primary Glioblastoma.
Ung TH; Ney DE; Damek D; Rusthoven CG; Youssef AS; Lillehei KO; Ormond DR
Neurosurgery; 2019 Mar; 84(3):687-695. PubMed ID: 29618103
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Evaluation of Neurological Assessment of the Neuro-Oncology Scale in Glioblastoma Patients.
Lee J; Park SH; Kim YZ
Brain Tumor Res Treat; 2018 Apr; 6(1):22-30. PubMed ID: 29644808
[TBL] [Abstract][Full Text] [Related]
3. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
Nayak L; DeAngelis LM; Brandes AA; Peereboom DM; Galanis E; Lin NU; Soffietti R; Macdonald DR; Chamberlain M; Perry J; Jaeckle K; Mehta M; Stupp R; Muzikansky A; Pentsova E; Cloughesy T; Iwamoto FM; Tonn JC; Vogelbaum MA; Wen PY; van den Bent MJ; Reardon DA
Neuro Oncol; 2017 May; 19(5):625-635. PubMed ID: 28453751
[TBL] [Abstract][Full Text] [Related]
4. Karnofsky Performance Scale and Neurological Assessment of Neuro-Oncology Scale as Early Predictor in Glioma.
Gunawan PY; Islam AA; July J; Patellongi I; Nasrum M; Aninditha T
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3387-3392. PubMed ID: 33247700
[TBL] [Abstract][Full Text] [Related]
5. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
[TBL] [Abstract][Full Text] [Related]
7. Early imaging marker of progressing glioblastoma: a window of opportunity.
Gatson NTN; Bross SP; Odia Y; Mongelluzzo GJ; Hu Y; Lockard L; Manikowski JJ; Mahadevan A; Kazmi SAJ; Lacroix M; Conger AR; Vadakara J; Nayak L; Chi TL; Mehta MP; Puduvalli VK
J Neurooncol; 2020 Jul; 148(3):629-640. PubMed ID: 32602020
[TBL] [Abstract][Full Text] [Related]
8. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
[TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
10. Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation.
Linhares P; Carvalho B; Figueiredo R; Reis RM; Vaz R
J Oncol; 2013; 2013():690585. PubMed ID: 24000284
[TBL] [Abstract][Full Text] [Related]
11. One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?
Heiland DH; Haaker G; Watzlawick R; Delev D; Masalha W; Franco P; Machein M; Staszewski O; Oelhke O; Nicolay NH; Schnell O
J Neurooncol; 2018 Nov; 140(2):385-391. PubMed ID: 30076585
[TBL] [Abstract][Full Text] [Related]
12. The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma.
Rahman M; Abbatematteo J; De Leo EK; Kubilis PS; Vaziri S; Bova F; Sayour E; Mitchell D; Quinones-Hinojosa A
J Neurosurg; 2017 Jul; 127(1):123-131. PubMed ID: 27689459
[TBL] [Abstract][Full Text] [Related]
13. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Value of NANO Scale Assessment in IDH-Wild-Type Glioblastoma Patients.
Kasper J; Wende T; Fehrenbach MK; Wilhelmy F; Jähne K; Frydrychowicz C; Prasse G; Meixensberger J; Arlt F
Front Oncol; 2021; 11():790458. PubMed ID: 34926307
[TBL] [Abstract][Full Text] [Related]
15. Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework.
Sughrue ME; Sheean T; Bonney PA; Maurer AJ; Teo C
Neurosurg Focus; 2015 Mar; 38(3):E11. PubMed ID: 25727220
[TBL] [Abstract][Full Text] [Related]
16. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
Youssef G; Wen PY
Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
[TBL] [Abstract][Full Text] [Related]
17. Imaging Criteria in Neuro-oncology.
Nowosielski M; Wen PY
Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.
Arvold ND; Armstrong TS; Warren KE; Chang SM; DeAngelis LM; Blakeley J; Chamberlain MC; Dunbar E; Loong HH; Macdonald DR; Reardon DA; Vogelbaum MA; Yuan Y; Weller M; van den Bent M; Wen PY
Neuro Oncol; 2018 Jun; 20(7):897-906. PubMed ID: 29788429
[TBL] [Abstract][Full Text] [Related]
19. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
20. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
Sharma M; Juthani RG; Vogelbaum MA
Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
